"The cancer treatment component of the center is comprised of the departments of Medical Oncology and Radiation Oncology. Primary modes of treatment are chemotherapy and radiation therapy. Radiation therapy is primarily provided through a TomoTherapy system. Additional services include a superficial treatment unit, High Dose Radiation (HDR) Brachytherapy and 3-D treatments. The diagnostic component of the cancer center provides a myriad of radiologic services and laboratory testing. Radiology services include CT scanning, mammography, bone density and radiologic x-rays, all of which are digital. The radiology services are accredited by the American College of Radiology (ACR) and the FDA."

During the past decade, Raleigh Regional Cancer Center conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 2 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Raleigh Regional Cancer Center" #1 collaborator was "Bristol-Myers Squibb" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator, "Sanofi" with 1 trials as a collaborator and "US Oncology Research" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Raleigh Regional Cancer Center" are "Breast Cancer" (2 trials) and "Rectal Cancer" (1 trials). Many other conditions were trialed in "Raleigh Regional Cancer Center" in a lesser frequency.

Most popular intervention types in "Raleigh Regional Cancer Center" are "Drug" (3 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "5-fluorouracil" (1 trials), "Cetuximab" (1 trials), "Cyclophosphamide" (1 trials), "Docetaxel" (1 trials) and "Doxorubicin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Raleigh Regional Cancer Center" are 2 trials for "Female" genders and 1 trials for "All" genders.

Currently, there are NaN active trials in "Raleigh Regional Cancer Center". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Raleigh Regional Cancer Center, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Raleigh Regional Cancer Center, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".